Advanced search
1 file | 1.31 MB Add to list

How public health services pay for radiotherapy in Europe : an ESTRO–HERO analysis of reimbursement

(2020) LANCET ONCOLOGY. 21(1). p.E42-E54
Author
Organization
Abstract
Reimbursement is a key factor in defining which resources are made available to ensure quality, efficiency, availability, and access to specific health-care interventions. This Policy Review assesses publicly funded radiotherapy reimbursement systems in Europe. We did a survey of the national societies of radiation oncology in Europe, focusing on the general features and global structure of the reimbursement system, the coverage scope, and level for typical indications. The annual expenditure covering radiotherapy in each country was also collected. Most countries have a predominantly budgetary-based system. Variability was the major finding, both in the components of the treatment considered for reimbursement, and in the fees paid for specific treatment techniques, fractionations, and indications. Annual expenses for radiotherapy, including capital investment, available in 12 countries, represented between 4 center dot 3% and 12.3% (average 7.8%) of the cancer care budget. Although an essential pillar in multidisciplinary oncology, radiotherapy is an inexpensive modality with a modest contribution to total cancer care costs. Scientific societies and policy makers across Europe need to discuss new strategies for reimbursement, combining flexibility with incentives to improve productivity and quality, allowing radiation oncology services to follow evolving evidence.
Keywords
Oncology, EXTERNAL-BEAM RADIOTHERAPY, RADIATION ONCOLOGY, PAYMENT SYSTEMS, CANCER CARE, COST, COUNTRIES, IMPLEMENTATION, GUIDELINES, EQUIPMENT, SURVIVAL

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.31 MB

Citation

Please use this url to cite or link to this publication:

MLA
Lievens, Yolande, et al. “How Public Health Services Pay for Radiotherapy in Europe : An ESTRO–HERO Analysis of Reimbursement.” LANCET ONCOLOGY, vol. 21, no. 1, 2020, pp. E42–54, doi:10.1016/s1470-2045(19)30794-6.
APA
Lievens, Y., Defourny, N., Corral, J., Gasparotto, C., Grau, C., Borras, J. M., & Consortium, E.-H. (2020). How public health services pay for radiotherapy in Europe : an ESTRO–HERO analysis of reimbursement. LANCET ONCOLOGY, 21(1), E42–E54. https://doi.org/10.1016/s1470-2045(19)30794-6
Chicago author-date
Lievens, Yolande, Noémie Defourny, Julieta Corral, Chiara Gasparotto, Cai Grau, Josep Maria Borras, and ESTRO-HERO Consortium. 2020. “How Public Health Services Pay for Radiotherapy in Europe : An ESTRO–HERO Analysis of Reimbursement.” LANCET ONCOLOGY 21 (1): E42–54. https://doi.org/10.1016/s1470-2045(19)30794-6.
Chicago author-date (all authors)
Lievens, Yolande, Noémie Defourny, Julieta Corral, Chiara Gasparotto, Cai Grau, Josep Maria Borras, and ESTRO-HERO Consortium. 2020. “How Public Health Services Pay for Radiotherapy in Europe : An ESTRO–HERO Analysis of Reimbursement.” LANCET ONCOLOGY 21 (1): E42–E54. doi:10.1016/s1470-2045(19)30794-6.
Vancouver
1.
Lievens Y, Defourny N, Corral J, Gasparotto C, Grau C, Borras JM, et al. How public health services pay for radiotherapy in Europe : an ESTRO–HERO analysis of reimbursement. LANCET ONCOLOGY. 2020;21(1):E42–54.
IEEE
[1]
Y. Lievens et al., “How public health services pay for radiotherapy in Europe : an ESTRO–HERO analysis of reimbursement,” LANCET ONCOLOGY, vol. 21, no. 1, pp. E42–E54, 2020.
@article{8664530,
  abstract     = {{Reimbursement is a key factor in defining which resources are made available to ensure quality, efficiency, availability, and access to specific health-care interventions. This Policy Review assesses publicly funded radiotherapy reimbursement systems in Europe. We did a survey of the national societies of radiation oncology in Europe, focusing on the general features and global structure of the reimbursement system, the coverage scope, and level for typical indications. The annual expenditure covering radiotherapy in each country was also collected. Most countries have a predominantly budgetary-based system. Variability was the major finding, both in the components of the treatment considered for reimbursement, and in the fees paid for specific treatment techniques, fractionations, and indications. Annual expenses for radiotherapy, including capital investment, available in 12 countries, represented between 4 center dot 3% and 12.3% (average 7.8%) of the cancer care budget. Although an essential pillar in multidisciplinary oncology, radiotherapy is an inexpensive modality with a modest contribution to total cancer care costs. Scientific societies and policy makers across Europe need to discuss new strategies for reimbursement, combining flexibility with incentives to improve productivity and quality, allowing radiation oncology services to follow evolving evidence.}},
  author       = {{Lievens, Yolande and Defourny, Noémie and Corral, Julieta and Gasparotto, Chiara and Grau, Cai and Borras, Josep Maria and Consortium, ESTRO-HERO}},
  issn         = {{1470-2045}},
  journal      = {{LANCET ONCOLOGY}},
  keywords     = {{Oncology,EXTERNAL-BEAM RADIOTHERAPY,RADIATION ONCOLOGY,PAYMENT SYSTEMS,CANCER CARE,COST,COUNTRIES,IMPLEMENTATION,GUIDELINES,EQUIPMENT,SURVIVAL}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{E42--E54}},
  title        = {{How public health services pay for radiotherapy in Europe : an ESTRO–HERO analysis of reimbursement}},
  url          = {{http://dx.doi.org/10.1016/s1470-2045(19)30794-6}},
  volume       = {{21}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: